trending Market Intelligence /marketintelligence/en/news-insights/trending/8ezqbzgewnkj-rbzn4hw2g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

CSPC Pharmaceutical FY'17 profit up 31.9% YOY

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

CSPC Pharmaceutical FY'17 profit up 31.9% YOY

CSPC Pharmaceutical Group Ltd. said its income was up 31.9% year over year during 2017.

The Chinese pharmaceutical company's 2017 profit attributable to shareholders totaled HK$2.77 billion, or 45.48 Hong Kong cents per share.

CSPC Pharmaceutical generated about HK$15.46 billion in full-year revenue, up 25% year over year. The figure includes HK$6.58 billion in sales from the innovative drug business and HK$4.79 billion from generic drugs, up 37.9% and 14.3% year over year, respectively.

Moving ahead, the company said its board proposed a dividend of 15 Hong Kong cents per share for 2017, compared to 12 Hong Kong cents for 2016.